Reimagine life beyond autoimmune disease
Zenas BioPharma (zenasbio.com) scores 71 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 26th percentile of 17128 Healthcare brands.
Zenas BioPharma is a biopharmaceutical company focused exclusively on developing late-stage therapies for autoimmune diseases. Its pipeline centers on two franchises, obexelimab (a biologic) and orelabrutinib (a small-molecule BTK inhibitor), aimed at addressing unmet needs across multiple autoimmune conditions. The company emphasizes scientific rigor combined with patient empathy, positioning itself as patient-centric while working toward transformative treatments for patients and caregivers affected by autoimmune disease.
| Brand Name | Zenas BioPharma |
|---|---|
| Domain | zenasbio.com |
| Industry | Healthcare |
| Main Competitors | argenx (83/100), UCB (89/100), Horizon Therapeutics (80/100), AbbVie (84/100), BeiGene (85/100), Alexion Pharmaceuticals (87/100), Amgen (90/100) |
Moz Domain Authority 32/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #2,352,021 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Enabling patients with autoimmune diseases to reimagine life" (Meta description: 8 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, Instagram, GitHub; no detected presence on X (Twitter), Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Zenas BioPharma?", Claude could identify the brand as of October 2026. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immune-based therapies for autoimmune diseases, with its lead asset obexelimab and rights to drugs like inebilizumab in certain territories outside the US. It went public on Na Best known for developing obexelimab and licensing autoimmune disease therapies for global markets outside the US.
When asked "Best brands similar to Zenas BioPharma?", Claude would recommend Zenas BioPharma as of October 2026. It's a notable player in the autoimmune biopharma space with a recent IPO, so it could come up in discussions of emerging immunology-focused drug developers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Zenas BioPharma's main competitors in Healthcare: argenx (83/100), UCB (89/100), Horizon Therapeutics (80/100), AbbVie (84/100), BeiGene (85/100).
Sources: Brand Analyzer scan
Zenas BioPharma has low AI-search visibility, scoring 24/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 42, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Zenas BioPharma official site
Zenas BioPharma scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Zenas BioPharma official site
Zenas BioPharma is a biopharmaceutical company that develops late-stage biologic and small-molecule therapies specifically for autoimmune diseases. It operates exclusively within the autoimmune disease space, aiming to bring transformative treatments to patients with significant unmet medical needs.
Sources: Zenas BioPharma official site
Zenas BioPharma develops and advances late-stage therapeutic candidates for autoimmune diseases. Its work centers on two franchises: obexelimab, a biologic, and orelabrutinib, a small-molecule BTK inhibitor, both designed to treat multiple autoimmune conditions. The company combines scientific research with a patient-focused approach to bring these therapies through clinical development.
Sources: Zenas BioPharma official site
Zenas BioPharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Zenas BioPharma official site
Zenas BioPharma's offerings are its two therapeutic candidates in development: obexelimab, a biologic therapy, and orelabrutinib, a small-molecule BTK inhibitor. Both are being developed to address unmet needs across multiple autoimmune diseases, representing the company's core franchises rather than commercially marketed products.
Sources: Zenas BioPharma official site
Zenas BioPharma is known for its focused pipeline of two late-stage autoimmune disease therapies: obexelimab, a biologic, and orelabrutinib, a small-molecule BTK inhibitor. The company's exclusive focus on autoimmune disease and its combination of a biologic and small-molecule franchise distinguishes its approach within the biopharmaceutical sector.
Sources: Zenas BioPharma official site
Zenas BioPharma's therapies are intended for patients and caregivers affected by autoimmune diseases. Additionally, the medical and scientific community involved in autoimmune disease research and treatment innovation engages with the company's work, including clinicians and researchers evaluating its late-stage therapeutic candidates.
Sources: Zenas BioPharma official site
Zenas BioPharma scores 24/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Zenas BioPharma has a weak AI-visibility profile at 24/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #2,352,021 (Tranco), open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 32/100. In a live check, Claude could already identify Zenas BioPharma from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Zenas BioPharma: Zaina AI (71/100), YourDOST (71/100), Zimmer MedizinSysteme (71/100), Zorgnet-Icuro (71/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.